Go Deep
Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,084 | -0.9 | 0.83 | 0.11 | 108.92 |
| Oct 2026 | 22,131 | -0.9 | 0.81 | 0.11 | 106.08 |
| Oct 2026 | 22,131 | -0.9 | 0.81 | 0.11 | 106.19 |
| Oct 2026 | 22,084 | -0.9 | 0.83 | 0.11 | 109.04 |
| Oct 2026 | 22,099 | -0.9 | 0.83 | 0.11 | 107.82 |
| Oct 2026 | 22,084 | -0.9 | 0.83 | 0.11 | 108.55 |
| Oct 2026 | 22,147 | -0.9 | 0.81 | 0.11 | 105.21 |
Sonoma Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 6,406,000.0 | 5,561,000.0 | 4,349,000.0 | 5,604,000.0 |
| Net Profit | -330,000.0 | -581,000.0 | -819,000.0 | -534,000.0 |
| EPS | -0.1 | — | -0.5 | -0.3 |
Sonoma Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 19,529,000.0 | 14,288,000.0 | 12,735,000.0 | 13,272,000.0 | — |
| Net Profit | -3,175,000.0 | -3,457,000.0 | -4,835,000.0 | -5,151,000.0 | — |
| EPS | -1.9 | -2.8 | -10.6 | -30.4 | — |
Sonoma Pharmaceuticals, Inc. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 13,960,000.0 | 13,693,000.0 | 14,740,000.0 | 16,231,000.0 | — |
| Total Liabilities | 10,865,000.0 | 9,282,000.0 | 8,603,000.0 | 8,254,000.0 | — |
| Total Equity | 3,095,000.0 | 4,411,000.0 | 6,137,000.0 | 7,977,000.0 | — |
Owes vs Owns
Sonoma Pharmaceuticals, Inc. owed $0.64 for every $1 it owned in Jun 2026, up from $0.51 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.64× | 0.78× | 0.68× | 0.58× | 0.51× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sonoma Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Mar 2026
Cash & short-term investments 17.2%Receivables 38.9%Inventory 26.2%Fixed assets (tangible) 6.5%Other assets 11.2%
How it's funded — Mar 2026
Short-term debt 1.6%Long-term debt 3.4%Payables 13.8%Other liabilities 59.1%Shareholders' equity 22.2%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2.4 | 5.4 | 3.1 | 3.8 |
| Receivables | 5.4 | 3.8 | 6.0 | 6.4 |
| Inventory | 3.7 | 2.9 | 2.7 | 2.9 |
| Fixed assets (tangible) | 0.9 | 0.3 | 0.7 | 0.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.6 | 1.3 | 2.2 | 2.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.2 | 0.2 | 0.3 | 0.4 |
| Long-term debt | 0.5 | 0.0 | 0.1 | 0.2 |
| Payables | 1.9 | 1.0 | 0.6 | 0.8 |
| Other liabilities | 8.3 | 8.1 | 7.6 | 6.8 |
| Shareholders' equity | 3.1 | 4.4 | 6.1 | 8.0 |
| Net tangible assets | 3.1 | 4.4 | 6.1 | 8.0 |
Sonoma Pharmaceuticals, Inc. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -3,933,000.0 | -88,000.0 | -2,398,000.0 | -6,152,000.0 | — |
| Investing Activities | -192,000.0 | -80,000.0 | -2,000.0 | -258,000.0 | — |
| Financing Activities | 477,000.0 | 3,030,000.0 | 1,676,000.0 | 2,489,000.0 | — |